文献速递流行病学与生物统计真实世界研究与卫生经济

患者与健康消费者组织的行业资助:系统综述与荟萃分析

Industry funding of patient and health consumer organisations: systematic review with meta-analysis.
PubMed 文献 · BMJ · 2020-01-22

该系统综述与荟萃分析纳入26项横断面研究,考察患者组织接受制药或医疗器械行业资助的情况。15项研究估计行业资助患病率范围为20%(12/61)至83%(86/104)。接受资助的患者组织中仅27%(175/642;95%CI 24%至31%)在网站披露该信息,且行业资助组织倾向于支持赞助者立场。

要点

  • 患者组织行业资助患病率估计范围为20%至83%。
  • 接受资助组织中仅27%在网站披露资助信息。
  • 行业资助组织在争议议题上倾向于支持赞助者立场。

核心结论

  • 行业对患者组织的资助似乎较为常见,患病率估计范围为20%至83%。
  • 少有患者组织制定管理企业赞助的政策,企业资助的透明度也不足。
  • 在少数分析资助与组织立场关联的研究中,行业资助组织倾向于持有有利于赞助者的立场。

研究设计与样本

  • 系统综述与荟萃分析,检索Ovid Medline、Embase、Web of Science、Scopus和Google Scholar自建库至2018年1月。
  • 纳入报告行业资助患病率、披露比例或资助与组织立场关联的观察性研究,共26项横断面研究符合纳入标准。
  • 采用Joanna Briggs Institute患病率研究清单修订版评估研究质量,GRADE评估证据质量。

主要发现

  • 15项研究估计行业资助患病率,范围为20%(12/61)至83%(86/104)。
  • 接受行业资助的患者组织中,27%(175/642;95%CI 24%至31%)在网站披露该信息。
  • 在提交给咨询的文件中,两项研究显示披露率差异很大(0%和91%),似反映相关政府机构披露要求的不同。
  • 管理企业赞助的组织政策患病率估计范围为2%(2/125)至64%(175/274)。
  • 四项研究分析行业资助与组织在一系列高度争议问题上立场的关系,行业资助组织通常支持赞助者的利益。

关键数值与推荐

  • 行业资助患病率估计范围为20%(12/61)至83%(86/104)。
  • 接受资助组织网站披露率为27%(175/642;95%CI 24%至31%)。
  • 组织管理企业赞助政策的患病率范围为2%(2/125)至64%(175/274)。

临床怎么用

  • 临床与科研人员应关注患者组织行业资助的普遍性及其对组织立场的影响。
  • 在采纳患者组织观点或合作时,需考量其资助披露的充分性及政策管理情况。
  • 需制定策略防止患者组织立场偏向赞助者利益而损害公众利益。

局限性

  • 仅基于26项横断面研究,部分结局研究数量较少。
  • 披露率与政策患病率估计异质性较大,受政府披露要求等因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate pharmaceutical or medical device industry funding of patient groups. DESIGN: Systematic review with meta-analysis. DATA SOURCES: Ovid Medline, Embase, Web of Science, Scopus, and Google Scholar from inception to January 2018; reference lists of eligible studies and experts in the field. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Observational studies including cross sectional, cohort, case-control, interrupted time series, and before-after studies of patient groups reporting at least one of the following outcomes: prevalence of industry funding; proportion of industry funded patient groups that disclosed information about this funding; and association between industry funding and organisational positions on health and policy issues. Studies were included irrespective of language or publication type. REVIEW METHODS: Reviewers carried out duplicate independent data extraction and assessment of study quality. An amended version of the checklist for prevalence studies developed by the Joanna Briggs Institute was used to assess study quality. A DerSimonian-Laird estimate of single proportions with Freeman-Tukey arcsine transformation was used for meta-analyses of prevalence. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to assess the quality of the evidence for each outcome. RESULTS: 26 cross sectional studies met the inclusion criteria. Of these, 15 studies estimated the prevalence of industry funding, which ranged from 20% (12/61) to 83% (86/104). Among patient organisations that received industry funding, 27% (175/642; 95% confidence interval 24% to 31%) disclosed this information on their websites. In submissions to consultations, two studies showed very different disclosure rates (0% and 91%), which appeared to reflect differences in the relevant government agency's disclosure requirements. Prevalence estimates of organisational policies that govern corporate sponsorship ranged from 2% (2/125) to 64% (175/274). Four studies analysed the relationship between industry funding and organisational positions on a range of highly controversial issues. Industry funded groups generally supported sponsors' interests. CONCLUSION: In general, industry funding of patient groups seems to be common, with prevalence estimates ranging from 20% to 83%. Few patient groups have policies that govern corporate sponsorship. Transparency about corporate funding is also inadequate. Among the few studies that examined associations between industry funding and organisational positions, industry funded groups tended to have positions favourable to the sponsor. Patient groups have an important role in advocacy, education, and research, therefore strategies are needed to prevent biases that could favour the interests of sponsors above those of the public. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42017079265.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Fabbri A, Parker L, Colombo C, et al. Industry funding of patient and health consumer organisations: systematic review with meta-analysis. BMJ. 2020. PMID: 31969320. doi:10.1136/bmj.l6925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。